WallStSmart

Merck & Company Inc (MRK)vsUniqure NV (QURE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 363400% more annual revenue ($65.77B vs $18.09M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

QURE

Avoid

30

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: -1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued

Intrinsic value data unavailable for QURE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

QURE1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
127.3%10/10

Revenue surging 127.3% year-over-year

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

QURE4 concerns · Avg: 2.8/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-228.2%2/10

ROE of -228.2% — below average capital efficiency

EPS GrowthGrowth
-18.2%2/10

Earnings declined 18.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : QURE

The strongest argument for QURE centers on Revenue Growth. Revenue growth of 127.3% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : QURE

The primary concerns for QURE are Price/Book, Profit Margin, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while QURE is a hypergrowth play — different risk/reward profiles.

QURE carries more volatility with a beta of 0.90 — expect wider price swings.

QURE is growing revenue faster at 127.3% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Uniqure NV

HEALTHCARE · BIOTECHNOLOGY · USA

uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?